Dirk Mendel Ph.D.
VP, Translational Biology
Dr. Mendel joined E-Scape Bio in late 2015. He brings 25 years of biotech and biopharma experience, during which time he has worked in several therapeutic areas and on a variety of compound types, including 6 small molecules (Sutent®, Palladia®, Xalkori®, Tamiflu®, Hepsera® and Vistide®) and 1 peptide (Parsabiv®) that have made it to market.
Having worked in all phases of the R&D pipeline, for most of the past 20 years he has focused on the translational aspects of drug development, leading translational efforts from lead optimization through clinical proof of concept to understand patient identification and stratification as well as the relationships between compound exposure and activity/toxicity to enable clinical candidate selection and early clinical development.
Immediately prior to joining E-Scape Bio, Dr. Mendel was VP and Global Head of Translational Medicine at MedImmune, the biologics arm of AstraZeneca, and was responsible for ensuring all projects had a translational strategy to inform clinical development. Before MedImmune, Dr. Mendel held various positions of increasing responsibility, leading groups of scientists and project teams from early discovery through clinical proof of concept at Gilead, SUGEN, Chiron, and KAI Pharmaceuticals. He has 3 issued patents and has co-authored more than 70 publications. Dr. Mendel earned his B.S. in Engineering from Stanford, his Ph.D. in Physiology from Dartmouth, and completed post-doctoral research at Stanford Medical School.